2025年半年度每股分配比例：每10股派发现金红利1.20元（含税），不送 红股，不以资本公积金转增股本。 2025年半年度利润分配以实施权益分派股权登记日登记的总股数为基数， 具体日期将在权益分派实施公告中明确。 证券代码：688163 证券简称：赛伦生物 公告编号：2025-020 上海赛伦生物技术股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 5 月 16 日召开 2024 年年度股东大会，审议通过了《关于提 请股东大会授权董事会进行 2025 年度中期分红的议案》，同意授权董事会在满足 现金分红条件，不影响公司正常经营和持续发展的情况下，在 2025 年中期（半 年度报告或第三季度报告披露期间）适当增加一次分红，制定并实施具体现金分 红方案。 授权事项如下：1、中期分红的前提条件：（1）公司在当期盈利、累计未分 配利润为正；（2）公司现金流可以满足正常经营和持续发展的需求。2、2025 年 中期现金分红上限为：不超过相应 ...

Core Viewpoint - The company has initiated the sales of its rabies immune globulin product, which is now listed on drug procurement platforms in certain provinces, marking a significant step in its market presence [1] Group 1: Product Development and Sales - The rabies immune globulin product is an existing product that had previously not been sold on a large scale due to distribution channel issues and allergic reactions [1] - Continuous process improvement research is being conducted on the product, with production planned for the second half of 2024 and ongoing efforts to list the product on procurement platforms across provinces in 2025 [1] Group 2: Market Position and Regulatory Status - The rabies immune globulin has a specific role in neutralizing the rabies virus and is used for preventive injections in individuals severely bitten by suspected rabid animals [1] - Currently, the company is the only manufacturer and seller of rabies immune globulin in the market [1] - The product is included in the National Essential Medicines List and the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List [1]

证券之星消息，8月20日，赛伦生物（688163）融资买入670.63万元，融资偿还529.86万元，融资净买入 140.77万元，融资余额1.52亿元，近3个交易日已连续净买入累计714.83万元，近20个交易日中有17个交 易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-20 | 140.77万 | 1.52亿 | 13.22% | | 2025-08-19 | 191.39万 | 1.50亿 | 12.84% | | 2025-08-18 | 382.67万 | 1.48亿 | 12.69% | | 2025-08-15 | -60.93万 | 1.44亿 | 12.39% | | 2025-08-14 | 558.12万 | 1.44亿 | 12.91% | 融券方面，当日无融券交易。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-20 | 1.52亿 | 140.77万 | 0.94% ...

Group 1 - The core viewpoint of the article is that Sairun Biotech (688163.SH) has not included its products in the national drug procurement led by the National Healthcare Security Administration [1] - The company currently has no plans to adjust the price of its anti-snake venom serum [1] - The anti-snake venom serum plays a crucial role in quickly neutralizing toxins, reducing harm to patients, shortening recovery time, improving prognosis, and decreasing treatment costs for complications caused by poisoning [1] Group 2 - The article highlights that with ongoing social progress and an increase in public health awareness and demand, the construction of a snakebite treatment system is expected to improve [1] - The key role and usage principles of anti-snake venom serum are anticipated to receive more attention and implementation in clinical settings [1]

Group 1 - A total of 155 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for 5 consecutive days or more as of August 11 [1] - The stock with the longest consecutive net inflow is Huicheng Environmental Protection, which has seen net inflows for 21 trading days [1] - Other notable stocks with significant consecutive net inflows include China High-Tech, Taijing Technology, Sailun Biology, Tanshan Explorer, Hengsheng Electronics, Three Gorges New Materials, New Jingang, and Limin Co., which have all recorded net inflows for 12 or 11 trading days respectively [1]

Group 1 - The core point of the announcement is the resolution of the first extraordinary general meeting of shareholders of Shanghai Sailun Biotechnology Co., Ltd. held on August 11, 2025, which included the approval of significant changes to the company's governance structure and operational scope [1][2][4]. Group 2 - The meeting was held at the company's headquarters in Shanghai, with all board members and supervisors present, ensuring a quorum for decision-making [2][3]. - Two main resolutions were passed: the cancellation of the supervisory board and amendments to the company's articles of association, which were approved by more than two-thirds of the voting rights held by shareholders present [4][5]. - The meeting was legally validated by the Shanghai Jintiancheng Law Firm, confirming that all procedures and voting results complied with relevant laws and regulations [5].

证券日报网讯 8月11日晚间，赛伦生物发布公告称，公司2025年第一次临时股东大会于2025年8月11日 召开，审议通过了《关于修订和制定公司部分治理制度的议案》等。 （文章来源：证券日报） ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-019 上海赛伦生物技术股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 8 月 11 日 （二） 股东大会召开的地点：上海赛伦生物技术股份有限公司（上海市青浦区 华青路 1288 号）会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 76 | | --- | --- | | 普通股股东人数 | 76 | | 2、出席会议的股东所持有的表决权数量 | 65,880,183 | | 普通股股东所持有表决权数量 | 65,880,183 | | 3、出席会议的股东所持有表决权数量占公司表决权数量 ...

上海市锦天城律师事务所 关于上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会的法律意见书 致：上海赛伦生物技术股份有限公司 上海赛伦生物技术股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会（下称"本次股东大会"或"会议"）于 2025 年 8 月 11 日在公司会议室召 开。上海市锦天城律师事务所（下称"本所"）经公司董事会聘请，委派吕希菁、 付慧琪律师（下称"经办律师"）出席会议，根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》（以下简称"《规则》"）和《上海赛伦生物技术股份有 限公司章程》（以下简称"《公司章程》"）的规定，就本次股东大会的召集和召 开程序、出席会议人员资格、召集人的资格、会议的表决程 ...

Core Insights - As of August 8, a total of 160 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is Huicheng Environmental, which has seen net buying for 20 trading days [1] - Other notable stocks with significant consecutive net inflows include China Baowu, Jichuan Pharmaceutical, Taijing Technology, Sairun Bio, Tanshan, Hengsheng Electronics, China High-Tech, Xinjin Steel, Limin Co., and CIMC Vehicles, with net inflows for 14, 13, 11, 11, 11, 11, 11, 10, 10, and 10 trading days respectively [1]